Comprehensive molecular profiling of 5,175 esophagogastric cancer (EGC) patients identified distinct molecular signatures for early-onset (< 50 years of age, EOEGC, n=530) versus average-onset (AOEGC, n=4,645) tumors.
EOEGC has increased frequency of CDH1 mutations, ARHGAP26 fusions, enrichment of epithelial mesenchymal transition (EMT) and angiogenesis pathways, decreased MAPK pathway activity, decreased frequency of TMB-high and dMMR/MSI-H, and a unique immune cell infiltrate with decreased M1 macrophages and increased M2 macrophages.
These unique differential characteristics present therapeutic opportunities but also demonstrate the limitations of currently approved therapies in this subset of patients.
Introduction: Regorafenib is a third-line option in metastatic CRC, often overshadowed by its limited efficacy and high toxicity. Yet, rare cases of deep and even… […]
Effect of elevated expression of LILRB4 and TSC22D3 on survival in lung cancer
Background: LILRB4 and TSC22D3 in Inflammation HER2/neu mutations or amplifications can activate STAT3 to promote inflammation and suppressing adaptive immune responses. Elevated systemic inflammation-immune index… […]
